The financial crisis could lead to greater use of cheap heating fuels and burning of waste at home, increasing risks to children’s health. This adds urgency to discussions taking place in preparation for the Fifth Ministerial Conference on Environment and Health in 2010. On 28-29 January 2009, European policy-makers are gathered in Luxembourg at the Thematic Meeting on Healthy Environments to recommend actions and policies to protect children’s health from Read the rest of this entry »
Archive for January, 2009
Foods Matter, the UK’s only magazine for those with food allergies and intolerances, is launching the first of its ‘tastings supplements’ for Food Allergy and Intolerance week. With comprehensive details and comments on over 200 allergen-free foods, the supplement forms part of the on-going Read the rest of this entry »
Cobalis Corp Gets Federal Court Approval To Launch Its Flagship Anti-Allergy Product PreHistin™
20 Jan 2009
Cobalis Corp. (OTC:CLSC), a pharmaceutical biotech Company specializing in the development of anti-allergy medications, announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan. 13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter Read the rest of this entry »
Schering-Plough Corporation (NYSE: SGP) announces the introduction of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy medicine in an easy-to-swallow liquid-filled capsule. Now available over-the-counter, CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the worst allergy symptoms without causing drowsiness.
"New CLARITIN(R) Liqui-Gels(R) is the Read the rest of this entry »
Probiotics Prevent IgE Associated Allergy Until Age 5 In Cesarean Delivered Children But Not In Total Cohort
16 Jan 2009
According to a recent study from the University and the University Central Hospital of Helsinki, Finland, no allergy-preventive effect is extended to age 5 years by perinatal supplementation with probiotics in babies at risk for developing allergies; protection is conferred only to Cesarean section babies
Childhood allergies have Read the rest of this entry »
Merck Statement In Response To The FDA’s Update Regarding A Safety Review Of SINGULAIR(R) (montelukast)
15 Jan 2009
Merck & Co., Inc. issued the following statement in response to the U.S. Food & Drug Administration’s (FDA’s) update on its safety review of SINGULAIR® (montelukast).
Merck stands by the proven efficacy and safety of SINGULAIR, a medicine that has been prescribed to tens of millions of patients with asthma and allergic rhinitis for more than 10 years. Nothing Read the rest of this entry »
New Mouse Model For Peanut Allergy
14 Jan 2009
Chicago researchers report the development of a new mouse model for food allergy that mimics symptoms generated during a human allergic reaction to peanuts. The animal model provides a new research tool that will be invaluable in furthering the understanding of the causes of peanut and other food allergies and in finding new ways to treat and prevent their occurrence, according to experts at the National Institute Read the rest of this entry »
Buy soma pills Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated Read the rest of this entry »
Circassia Completes Patient Recruitment For Phase II Clinical Trial Of Toleromune(R) Allergy Treatment
08 Jan 2009
Circassia Ltd, a specialty biopharmaceutical company focused on allergy and critical care, announced that following successful clinical results achieved in 2008 with its ToleroMune(R) anti-allergy technology, the company has now completed patient recruitment for a further phase II clinical trial in cat Read the rest of this entry »
Amira Announces The Successful Completion Of GLP Toxicity Studies For A Novel DP2 Antagonist
07 Jan 2009
discovered oral drug candidate for the treatment and control of inflammatory
and allergic diseases linked to the arachidonic acid pathway, is on target
for submission of an IND to the U.S. Food and Drug Administration (FDA) by
mid-2009 following the successful completion of Good Laboratory Practices
(GLP) toxicity studies.
AM211 is an oral, selective antagonist of the Read the rest of this entry »
Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy due to food gluten intolerance in genetically predisposed people. While GSE was thought to be a rare disease in the past and was believed to be essentially a disease of Europeans, recent screening studies showed that GSE is one of the most frequent genetically based diseases occured worldwide. Iron deficiency anemia Read the rest of this entry »
Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found. University of Manchester scientists found that pills used to treat everyday fungal infections greatly improved symptoms of asthma in those patients that had an allergic reaction to one or Read the rest of this entry »
Researchers in Germany are reporting an advance toward development of technology that could make life easier for millions of people allergic to plant pollen. It could underpin the first automated, real-time systems for identifying specific kinds of allergy-inducing plant pollen circulating in the air. Their study is in the current issue of ACS’ Analytical Chemistry, a semi-monthly journal.
In Read the rest of this entry »